COVID-19 grants and funding
The subsidy landscape is responding quickly to the COVID-19 virus and the problems this crisis causes world-wide. A lot of new funding opportunities are being released to assist researchers and companies with their Research and Development activities against COVID-19. This overview of all available COVID-19 grants and funding opportunities will be updated regularly. Catalyze can help you to find what you need in this rapidly changing subsidy landscape and is available to assist you in writing successful proposals.
Available COVID-19 grants
European Commission Emergency Calls Under Horizon Europe
1. FAIR and open data sharing in support to European preparedness for COVID-19 and other infectious diseases (RIA)
Subsidy: €12M
Funding rate: 100%
Deadline: 6 May 2021
Project duration: No limit; up to 4 years is recommended.
Total budget: €12M
Consortium: At least three legal entities established in different Member States or Associated Countries.
Scope: Proposals should facilitate and accelerate the access to, and the linking of data and metadata on SARS-CoV-2 and COVID-19, including through the European COVID-19 Data Portal, the Versatile Emerging infectious disease Observatory (VEO) and other relevant initiatives, with the emphasis on identifying and tracking of new SARS-CoV-2 variants and creating appropriate links with serology and other host data.
Read more about FAIR and open data sharing in support to European preparedness for COVID-19 and other infectious diseases (RIA)
2. Research infrastructure services for rapid research responses to COVID-19 and other infectious disease epidemics (RIA)
Subsidy: €21M
Funding rate: 100%
Deadline: 6 May 2021
Duration: No limit; up to 4 years is recommended.
Total budget: €21M
Consortium: At least three legal entities established in different Member States or Associated Countries.
Scope: Proposals under this action, will integrate research infrastructure services to form a comprehensive and inclusive portfolio to support research in response to infectious disease epidemics or underpinning respective forefront research in the field.
Read more about Research infrastructure services for rapid research responses to COVID-19 and other infectious disease epidemics (RIA)
3. Vaccines & therapeutic clinical trials to boost COVID-19 prevention and treatment (RIA)
Subsidy: €3-10M
Funding rate: 100%
Deadline: 6 May 2021
Duration: No limit; up to 4 years is recommended.
Total budget: €60M
Consortium: At least three legal entities established in different Member States or Associated Countries.
Scope: Proposals submitted under this expression of interest should aim to further develop promising therapeutic or prophylactic candidates against SARS-CoV-2/COVID-19.
Read more about Vaccines & therapeutic clinical trials to boost COVID-19 prevention and treatment (RIA)
4. Cohorts united against COVID-19 variants of concern (RIA)
Subsidy: €7-10M
Funding rate: 100%
Deadline: 6 May 2021
Duration: No limit; up to 4 years is recommended.
Total budget: €30M
Consortium: At least three legal entities established in different Member States or Associated Countries. Strong collaboration with regional public health and regulatory authorities is strongly encouraged.
Scope: Proposals submitted under this expression of interest are expected to build on existing large-scale, multi-centre, regional or international cohorts worldwide and/or establish new ones linked to those.
Read more about Cohorts united against COVID-19 variants of concern (RIA)
Coalition for Epidemic Preparedness Initiative Calls
CEPI: Broadly protective vaccine against SARS-CoV-2 variants (BPCoV2)
Subsidy: not specified
Total Budget: $200M (for both BPCoV2 and BPBC)
Deadline: 31 May 2021 (Application will require one step, the submission of an Expression of Interest (EOI). An EOI may be submitted at any time and reviews will occur on a bi-monthly rolling basis.)
Project duration: 2 years
Consortium: Single applicant or a consortium are both eligible. This call is open, worldwide, to research and development organisations with expertise in vaccine development (at least one of the partners should have experience in human vaccine development and have a track record of bringing vaccine candidates through to human clinical trials in the past 5 years).
Scope: The main focus of this call is the research and development of novel immunogens for vaccine constructs able to elicit durable broadly protective responses.
Developed vaccine should be a broadly protective vaccine against new emerging variants and variants of concern of the SARS-CoV-2 virus (BPCoV2). Projects should aim to achieve clinical proof-of-concept.
Read more about CEPI: Broadly protective vaccine against SARS-CoV-2 variants (BPCoV2)
CEPI: Broadly protective Betacoronavirus (BPBC) vaccine
Subsidy: not specified
Total Budget: $200M (for both BPCoV2 and BPBC)
Deadline: 1 October 2021 (Application includes the submission of an Expression of Interest (EOI) and an invitation to submit a full proposal. An EOI may be submitted at any time and reviews will occur on a bi-monthly rolling basis.)
Project duration: 4 years
Consortium: Single applicant or a consortium are both eligible. This call is open, worldwide, to research and development organisations with expertise in vaccine development (at least one of the partners should have experience in human vaccine development and have a track record of bringing vaccine candidates through to human clinical trials in the past 5 years).
Scope: The main focus of this call is the research and development of novel immunogens for vaccine constructs able to elicit durable broadly protective responses.
Developed vaccine should be a broadly protective Betacoronavirus (BPBC) vaccine. Projects should aim to demonstrate clinical proof-of-concept.
Read more about CEPI: Broadly protective Betacoronavirus (BPBC) vaccine
Covid-X
Covid-X – Open Call #2
Subsidy: Single solutions: Max €100,000
Team solutions: Max €150,000 (€100,000 for the tech provider and €50,000 for the clinical partner).
Total Budget: 7 single solutions and 7 team solutions will be funded.
Deadline: 1st Stage: 22 July 2021
2nd Stage: 16 September 2021
Funding rate: 100%
Consortium: The call is open to companies (single solutions: SMEs and Start-Ups) and consortia of companies (team solutions: 1 SME or Start-Up + Healthcare provider), established in one of the EU Member States or an H2020 Associated country.
Scope: The COVID-X project aims to place new products and services in the market with the goals of fighting against the COVID-19 pandemic. The funding is invested in products with Technology Readiness Level (TRL) 7+ and/or in the process of CE marking, covering two profiles:
- Single players (EU Tech SMEs / Start-Ups) validating their solutions at one of COVID-X clinical partners (located in Italy, Spain, and Sweden).
- Team players (Tech Provider working with a Healthcare provider that will validate the solution).
The solutions are required to address one of the six defined clinical challenges in the coronavirus patient’s journey:
- Early detection – prevention
- Innovative diagnostics
- Personalized care
- Remote care
- Healthcare continuity
- Recovery.
Team solutions can also address other challenges as long as the solution is TRL 7+ and addresses at least one of the following areas: diagnostics, prevention, treatment, or rehabilitation of COVID-19 patients.
Read more about this Covid-X call.
Expired COVID-19 grants
NIH: Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)
Subsidy: max. $1,500,000
Deadline: Expired
Project duration: 5 years
Consortium: only the US entities are eligible
Scope: The purpose of the FOA is to establish Serological Sciences Centers of Excellence with the goal of:
- identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection;
- understanding the mechanisms driving the serological, humoral and cellular immune responses;
- determining host, genetic, and environmental modifiers of the immune response;
- determining the serological correlates of disease pathogenesis and protection against future infection;
- defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing.These U54 Centers will be part of a Serological Sciences Network (SeroNet). Other components of the Network will include Serological Sciences Research Projects (U01), the FNLCR Serology Laboratory, Serological Capacity Building Centers (CBC) and a Serological Sciences Network Coordinating Center (SSNCC).
NIH: NIAID – Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01, Clinical Trial Not Allowed) – PAR-20-178
Subsidy: no limit
Deadline: Expired
Consortium: Both US and non-US for profit and non-profit organizations can apply.
Scope: The purpose of this grant is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Examples of research areas are: studies to understand the viral infection, replication and pathogenesis, studies to understand viral transmission, identification and characterization of immunity, development of clinical diagnostic tests and therapeutics (in vitro, ex vivo or animal models), vaccines, and more.
NIH: NIAID- Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21, Clinical Trial Not Allowed) – PAR-20-177
Subsidy: $275,000 (max. $200,000 in one year)
Deadline: Expired
Consortium: Both US and non-US for profit and non-profit organizations can apply.
Scope: The purpose of this grant is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Examples of research areas are: studies to understand the viral infection, replication and pathogenesis, studies to understand viral transmission, identification and characterization of immunity, development of clinical diagnostic tests and therapeutics (in vitro, ex vivo or animal models), vaccines and more.
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
Subsidy: no limit
Deadline: Expired
Consortium: All researchers from anywhere in the world. Both for-profit and non-profit organizations are eligible.
Scope: projects must fall under one of the areas of interest.
- Area of interest #7: emerging diseases diagnostics: diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
- Area of interest #8: Influenza and emerging infectious diseases vaccines: COVID-19 vaccine
- Are of interest #9: influenza and emerging infectious diseases therapeutics: COVID-19 therapeutics
- Area of interest #17: (NEW) Advanced Manufacturing technologies: The development and demonstration of innovations and enhancements to manufacturing platforms to support the development of necessary medical countermeasures including vaccines and therapeutics in prevention, preparation, and response to COVID-19.
Read more about this call or visit the BARDA website.
NIH: NIAID- Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21, Clinical Trial Not Allowed) – PAR-20-177
Subsidy: $275,000 (max. $200,000 in one year)
Deadline: Expired
Project duration: 2 years
Consortium: Both US and non-US for profit and non-profit organizations can apply.
Scope: The purpose of this grant is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Examples of research areas are: studies to understand the viral infection, replication and pathogenesis, studies to understand viral transmission, identification and characterization of immunity, development of clinical diagnostic tests and therapeutics (in vitro, ex vivo or animal models), vaccines and more.
NIH: Rapid Acceleration of Diagnostics (RADx) initiative
Subsidy: no limit (total budget $500M)
Deadline: a rolling basis and will be reviewed within a week of receipt. Progression to ‘ deep dive stage’ upon invitation.
Project duration: depends on development stage, support incl. commercialization and product distribution
Consortium: US scientists and inventors
Scope: To address the COVID-19 pandemic, this program is anticipated to support the fast track development of new tests with improved technical performance and convenience, such as point-of-care and home devices, as well as innovations that make current lab tests faster, more efficient, and more widely accessible. Focus is on improving analytical or operational performance, improving access and reducing cost of testing. NIBIB will consider innovations at all stages of readiness from early to late stage and from novel testing strategies to optimization of existing SARS-CoV-2 testing approaches. NIBIB will support the full range of product development including commercialization and product distribution. NIH will supply the needed budget, partnerships and other resources to fully deploy successful tests to the public on the shortest possible timeline. NIH will negotiate cost sharing with for-profit institutions as appropriate.
European COVID-19 grants
Vinnova- Innovation projects in the health field that dampen the prevalence and effects of the covid-19 pandemic
Subsidy: up to 5M SEK, co-financing is required
Deadline: Expired
Consortium: consortium must consist of at least 2 partners. One from business or health care and other from the following sectors: health care, public sector, academia, business and civil society.
Scope: Health-related innovation projects and feasibility studies are funded within the call for proposal. These should help to curb the spread and effects of the covid-19 pandemic and prevent future pandemics. The results of the innovation projects should be implemented and utilized already during the ongoing pandemic, and the results of the feasibility studies will lead to increased preparedness for future pandemics.
Vinnova- Pre-studies for innovation projects in the health area that prevent future pandemics
Subsidy: up to 1M SEK, co-financing is required
Deadline: Expired
Consortium: consortium must consist of at least 2 partners. One from business or health care and other from the following sectors: health care, public sector, academia, business and civil society.
Scope: Pre-health studies to strengthen preparedness for future pandemics.
MedTech OITBs join forces in the fight against COVID-19
Subsidy: TBD
Deadline: Expired
Project duration: TBD
Consortium: (TBD); pan-European SMEs
Scope: Innovative SMEs working on the development of solutions to fight the virus will be able to apply to this call. The three MedTech Open Innovation Testbed (OITBs): TBMED, MDOT and SAFE-N-MEDTEC thus initiate a call for expressions of interest from MedTech SMEs performing COVID-19-related developments. Support will be provided in the following ways:
- TBMED offers services to SMEs from the high-risk medical devices sector, particularly with regard to characterization, prevention, diagnosis, treatment, follow-up and the forecast of patient prognosis related to COVID-19. Such services include, among others, early dialogues with the Basque HTA office, expert advice for regional and/or multinational clinical trials on COVID-19 and the assessment of needs of such companies regarding clinical trials.
- MDOT members who develop routines and processes to accelerate the conformity assessment of medical devices, offer consultation regarding regulatory affairs and technology development in the fields of inhalation technologies and environmental sensors.
- SAFE-N-MEDTECH with its key expertise in nano-enabled medical technologies, offers characterization, preclinical validation, access to biobanks and patient samples, scale up and regulatory support, technology assessment and horizon scanning.
MERCK KGaA: Research Grant for pandemic preparedness
Subsidy: up to €500,000/year
Deadline: Expired
Project duration: 3 years with the option of extension
Consortium: Globally, scientists in all career stages who are affiliated with any research-based institution, university or company.
Scope: The recent COVID-19 pandemic shows that pandemic preparedness and having the right products and technology to fight infectious diseases with epidemic and pandemic potential is of utmost importance.
Proposals will be considered that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.
Pre-outbreak R&D Preparedness for pandemic disease:
- Assessing the priority of pathogens and diseases with epidemic threat
- Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats
- Innovative technologies for better personal protection equipment for infection control
Response during outbreak:
- Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation.
- Fast-track identifying, testing and production of effective drugs and vaccines during outbreak
AMable: Call for Solution Ideas (COVID-19)
Total budget: €350,000
Subsidy: €10,000 per challenge
Deadline: Expired
Project duration: 6-12 weeks
Consortium: An entity that applies for financial support needs to be a natural person or a legally recognised company of any type, registered within the European Union or a country that is linked to the H2020 program. Preference will be given to SMEs and midcaps. Research and technology development organisations are not eligible, nor consortium members.
Scope: Support activities that propose a realistic solution to a practical challenge. Challenges that society currently sees in coping with the COVID-19 pandemic. The AMable consortium will publish these challenges in so called “challenge sets” on its web site. These challenges will be regularly updated. When talking about challenges from such a challenge set, we mean e.g. a lack of equipment, helpful tools, replacement parts or parts that enable additional functionality. Overall, such challenges need to be solved when additive manufacturing provides a solution.
The applicants need to provide the following to be selected for support:
- A solution idea that would solve the selected challenge by additive manufacturing. The proposal needs to sketch the baseline of that idea.
- A list of tasks that need to be addressed to create the solution and the support that the proposer expects from the AMable consortium.
- List of the proposer’s expected effort to develop a first prototype of the solution, budget for personnel cost and consumables. (do not address cost of the support from AMable experts here)
German COVID-19 grants
Deutsche Forschungsgemeinschaft (DFG)- Call for Multidisciplinary research into Epidemics and Pandemics in Response to the Outbreak of SARS-CoV-2
Deadline: Expired
Consortium: Researchers (single applicant or consortium) based at universities, universities of applied sciences, non-university research institutions and healthcare facilities. Applicants should aim to cooperate with international researchers.
Scope: Funding is available for multi-disciplinary projects addressing the prevention, early detection, containment and investigation of the causes, impacts and management of epidemics and pandemics, taking the example of SARS-CoV-2 and other microorganisms and viruses that are pathogenic to humans. This includes for example, the investigation of:
- The challenges and effects of an epidemic or pandemic and of measures taken for healthcare systems;
- Psychological, social and cultural factors in the emergence, spread and treatment of epidemics and pandemics and the legal and ethical implications;
- The impacts on global and regional economic development, production and value creation chains, logistics, transport and communication;
- Fundamental biological and medical aspects of a pathogen and the associated symptoms, as well as therapeutic methods or preventive measures in combination with one or more of the above topic areas.
Read more about this call or visit the DFG website.
Nordic COVID-19 grants
(Sweden) FORMAS: Urgent grants 2020 to secure access to data or research materials
Subsidy: Costs corresponding to the urgent need.
Deadline: Expired
Consortium: Participating researchers must have obtained their doctoral degree. Grants for research projects may only be administered by a Swedish university, college or other Swedish public organisation that meets Formas’ criteria for administrating organisations.
Scope: In view of Covid-19 and the current situation in Sweden and the world, Formas’ Research Council has decided to open its urgent call immediately. Formas wants to provide the opportunity to collect data and research materials of an urgent nature to ensure the future availability of research.
Applications are welcome within all Formas’ areas of responsibility that demonstrate an urgent need to secure future access to data (measurement data, collection of samples, etc.) or other research materials (interviews, participating observations, etc.). Applications from all scientific disciplines are welcome: the humanities, natural sciences, social sciences and technology, as well as for interdisciplinary approaches.
Other COVID-19 grants
France: ANR Recherche-Action Covid-19
Subsidy: max. €150,000
Deadline: Expired
Consortium: Main applicant: a full-time researcher who is a member of a French organization or research institution or of a company with headquarters located in France.
Scope: This call aims to complement the initial action of Flash COVID-19 and addresses the following five priorities:
- Epidemiological studies (i.e. New methods of diagnosing infection and asymptomatic carriage and studies of seroprevalence)
- Physiopathogenesis of the disease (i.e. new therapeutics; development of animal and cellular models of the disease; evolution of the immune response, nature and duration of acquired immunity)
- Infection prevention and control (i.e. mode of virus transmission and study of human and environmental factors influencing)
- Ethics and social dynamics (i.e. research and care ethics and human rights; Communication and crisis management)
- Global issues of the Covid-19 epidemic (i.e. understanding of the ecological, environmental and human factors at the origin of the emergence of the pandemic and identification of practices to limit the risks future (including international agreements); macro and micro-economic impact and on trade flows of goods and services (including financial)
France DIM Elict: special call for proposals development of innovative technologies & methods to fight SARS-COV-2
Subsidy: €15,000 of running costs and/or human resources and/or €30,000 of equipment
Deadline: open until the further notice (the end of the crisis)
Consortium: Any research team (laboratories, likely non-profit organizations) from the Ile de France region (The region is made up of eight administrative departments: Paris, Essonne, Hauts-de-Seine, Seine-Saint-Denis, Seine-et-Marne, Val-de-Marne, Val-d’Oise and Yvelines) can apply with a project linked to the infectious agent SARS-CoV-2
Scope: The DIM ELICIT would like to support projects developing innovative technologies and methods regarding the analysis, diagnosis and/or treatment to fight SARS-CoV-2.
The technologies targeted in this call will have to belong to at least one Core technologies and one End-user applications:
Core technologies
- Microfludics
- Biophotonic and waves
- Image analysis and Big Data
End-user applications
- Single Cell/Single molecule
- Organ on chips
- Technologies for in vivo biology
- High Tech – Low Cost technologies
Note: Projects will have to be written in English. The projects submitted must target the acquisition of knowledge.
UK Research and Innovation (UKRI) – Get funding for ideas that address COVID-19
Subsidy: No limit
Deadline: Open (apply at any time)
Consortium: UK based business at any stage or size. Researchers holding existing UKRI standard grants can apply to switch their funding to address the objectives of this call.
Scope: Proposals are invited for short-term projects addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.
UKRI will support excellent proposals which meet at least one of the following:
- New research or innovation with a clear impact pathway that has the potential (within the period of the grant) to deliver a significant contribution to the understanding of, and response to, the COVID-19 pandemic and its impacts.
- Supports the manufacture and/or wide scale adoption of an intervention with significant potential
- Gathers critical data and resources quickly for future research use
UKRI: COVID-19 Rapid Response Rolling Call
Subsidy: no max
Deadline: 1 April 2021
Consortium: Academic Principal Investigators hosted by a UK institution (eligible for UKRI funding) or SMEs, government arm’s length bodies, and NHS organisations, and equivalent UK authorities are also encouraged to apply.
Scope: The research scope of this call is as below:
- Virology, Immunity and Pathophysiology;
- Diagnostics;
- Epidemiology (Transmission, Disease Susceptibility and Severity, Control and Mitigation);
- IPC and PPE;
- Public Health, Media and Communication (Public Health; Media and communication);
- Clinical Management;
- Primary, Adjunctive and Supportive Therapies;
- Vaccines;
- Health and Care Delivery;
- Underpinning
US COVID-19 grants
SBIR/STTR Phase I Proposals Addressing COVID-19
Subsidy: $150,000 (up to $256,000)
Deadline: Expired
Full proposal upon invitation only.
Consortium: US-based small businesses can apply as single applicant or in a consortium. Additional requirements of SBIR & STTR apply
Scope: Focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations.
Note: when awarded a phase I grant, businesses are allowed to apply for a phase II grant (up to $1,000,000) 6-24 months after beginning phase I.
NIH: Rapid Acceleration of Diagnostics (RADx) initiative
Subsidy: no limit (total budget $500M)
Deadline: a rolling basis and will be reviewed within a week of receipt. Progression to ‘ deep dive stage’ upon invitation.
Consortium: US scientists and inventors
Scope: To address the COVID-19 pandemic, this program is anticipated to support the fast track development of new tests with improved technical performance and convenience, such as point-of-care and home devices, as well as innovations that make current lab tests faster, more efficient, and more widely accessible. Focus is on improving analytical or operational performance, improving access and reducing cost of testing.
NIBIB will consider innovations at all stages of readiness from early to late stage and from novel testing strategies to optimization of existing SARS-CoV-2 testing approaches. NIBIB will support the full range of product development including commercialization and product distribution. NIH will supply the needed budget, partnerships and other resources to fully deploy successful tests to the public on the shortest possible timeline. NIH will negotiate cost sharing with for-profit institutions as appropriate.
Closed calls
Austrian Research Promotion Agency (FFG)- Emergency call to research covid-19: KLIPHA-COVID19: Promotion of corporate projects and clinical studies
Subsidy: €3M
Deadline: expired
Consortium: Austrian companies of all sizes.
Scope: Research projects and clinical studies designed to investigate the effectiveness of existing drugs in the fight against corona. Research projects dealing with the biology of the virus and its transmission, infection prevention and control, and the research and development of therapeutic methods and new diagnostic approaches can also be submitted.
Luxemburg National Research Fund – COVID-19: Launch of FNR fast-track Call
Subsidy: max. €50,000 (co-funding; short projects); funding for longer-term projects is higher.
Deadline: expired
Consortium: Public institutions performing research in Luxembourg, Non-profit associations, societal impact companies (SIS), and foundations engaged in research in Luxembourg. Collaboration with relevant international partners is encouraged.
Scope: The Luxembourgish research community has created a COVID-19 Task Force in order to coordinate response activities, including the FNR and the major Luxembourgish research institutions. Projects submitted to this call can cover all research domains and disciplines but must be aligned with the WHO’s Coordinated Global Research Roadmap: 2019 Novel Coronavirus (March 2020 version). Proposals for long-term research projects tackling COVID-19 research questions can also be submitted to the FNR CORE 2020 (deadline 4 May 2020) call or the FNR OPEN 2020 (deadline 4 May 2020) call.
German Federal Ministry of Education and Research- Call for funding to research COVID-19 following the outbreak of SARs-CoV-2.
Subsidy: module 1 and 2: €2M, Module 3: €500,000, Module 4: €50,000
Deadline: expired
Consortium: State and state-recognized universities and non-university research institutions, departmental research institutions, institutions of the public health system and health care providers and commercial companies are eligible to apply.
Scope:
- Module 1: Combating COVID-19 through early clinical studies for the application of approved therapeutic approaches to Sars-CoV-2.
- Module 2: Control of COVID-19 through new therapeutic and diagnostic approaches.
- Module 3: Research contributing to understanding the virus and its spread
- Module 4: Support for ongoing research projects on corona viruses.
Read more about this call or visit the website.
EUREKA: Multilateral call for solutions for COVID-19 Echo Period – Life without a vaccine
Subsidy: country specific
Deadline: expired
Project duration: max. 1 year
Consortium: participating countries: Austria, Canada, Denmark, France, The Netherlands, Spain, Turkey. The consortium should include at least two organisations independent of each other from at least two of the participating countries.
Scope: Participants are invited to submit research and innovation project proposals aiming to provide short to medium-term responses to COVID-19 specific needs. These may include (but are not limited to):
- Infection prevention and protection
- Sanitation technology
- Diagnostics and testing
- Therapeutics, vaccines and medicines
- Disease-tracking technology, analytical solutions for health systems
- Smart technology for COVID-19 patients
- Smart technologies and support systems for critical production and supply chains under lockdown
- Safe mobility: migration data and trends, regional risk monitoring, protection of isolated and risk groups, safe use of public transports
- Education technologies and digital workplace.
Note: Product, service or process implementation or market launch should happen no later than 6 months after project completion.
EUREKA: Solutions for the next human high-impact pandemic
Subsidy: varies per country (for NL max. €350,000, 25-50% funding rate).
Deadline: expired
Project duration: up to 3 years (Projects Result Implementation: Up to 24 months after project completion preference for shorter launches)
Consortium: The consortium should include at least two organisations independent of each other from two of the participating countries. Belgium, Canada, Estonia, Finland, France, Netherlands, South Africa, Spain, Sweden, Turkey.
Scope: Participants are invited to submit research and innovation project proposals aiming to provide solutions and preparedness for highly contagious human infectious disease pandemics which inflict a high impact on society. These can include (but are not limited to):
-Technologies enabling local resilience or self sufficiency
– Medical intervention robotics
– Infection prevention and protection
– Prevention of antibiotic resistance
– Sanitation technology
– Diagnostics and testing
– Therapeutics, vaccines and medicines
– Medical intervention robotics
– Disease-tracking technology
– Smart technologies for critical production and supply chains under lockdown
– Education technologies and digital workplace
– Govtech/Open data and Big Data
The product, process or service must be innovative and there must be a technological risk involved.
Israel Innovation Authority- Call for Proposals for R&D Plans of Industrial Products for the Prevention and Treatment of the COVID-19 (Coronavirus)
Subsidy: support of 30-70% of the approved R&D expenses
Deadline: expired
Consortium: Israelian manufacturing companies
Scope: The aim is to aid with R&D and technological innovation plans of manufacturing plants making industrial products intended for the prevention and treatment of the COVID-19. This could include the development of products, raw materials, innovative technologies and manufacturing processes, practical demonstrations, development of prototypes in the final stages of R&D or developing a scaling process for the transition from experimental production to mass-production.
The proposed plans will accelerate solutions for prevention and treatment of the COVID-19 virus and must be technologically innovative relatively to the company’s capabilities as well as generate value in dealing with the virus.
Science Foundation Ireland, Enterprise Ireland, IDA Ireland: COVID-19 Rapid Response Funding Call
Deadline: expired
Consortium: Applications from organizations based in Ireland: any Research Performing Organisation (RPO); a client company of one of the following government agencies Enterprise Ireland, IDA Ireland, Údaras Na Gaeltachta or Local Enterprise Office (LEO); or any combination of these is eligible. Applications from other organisations, outside those referenced above, are also welcome (prior to submission contact covid19@sfi.ie to confirm eligibility).
Scope: The aim is to incentivise RD&I activities that will impact positively on the current crisis. These activities might include the development of innovative solutions based on new, blended or alternative approaches and methodologies to address immediate national needs. Applications that propose the adaptation or repurposing of existing products, processes and technologies are also strongly encouraged.
Problem areas include, but are not limited to:
- Contact tracing and role of data analytics;
- Frontline healthcare (supply of ventilators, use and supply of personal protective equipment and infection prevention and control (IPC) methods etc);
- Monitoring the impact and effectiveness of control and mitigation measures;
- Re-purposing of existing technologies, products or processes;
- Rapid, reliable, diagnostic testing and sampling optimisation;
- Supporting essential behaviours of self-isolation and social distancing;
- Mitigation measures relating to the disruption that the crisis is having on Irish society, including impact on essential services and supply chains;
- Epidemiological and sero-epidemiological studies, including novel approaches to better understand transmission and spread of virus (relevant to humans and animals) and to evaluate the potential impact of control measures.
Spanish Instituto de Salud Carlos III- Urgent request for expressions of interest for research projects on Sars-CoV-2 and disease COVID-19
Subsidy: total budget available €24M
Deadline: expired
Consortium: Universities, other non-profit and for-profit (private) organisation can apply.
Scope: Proposals must be appropriate to the emergency and, allow immediate implementation and start-up in the National Health System, with concrete, early results applicable to the current situation. These proposals may be based on currently existing activities. The scope of these proposals may be:
- Techniques for rapid virologic diagnosis of SARS-CoV-2
- Clinical-biological-molecular characterization of COVID-19 disease, stages, prognostic stratification and complications.
- Development of innovative therapies, new antiviral, antiseptic and disinfectant molecules against SARS-CoV-2. Antiviral resistance studies. Effectiveness of non-pharmacological, prophylactic and therapeutic interventions.
- Characterization of the SARS-CoV-2 virus, genetic and antigenic variation, the immunological response and the virus-host interaction.
- Vaccine development, efficacy and applicability.
- Epidemiological surveillance of SARS-CoV-2 and molecular epidemiology. Environmental and social factors of the spread. Risk factors and population dynamics of SARS-CoV-2 infection.
- Socio-economic impact of the disease COVID-19. Use of primary care resources, general hospital resources, and critical care resources.
- Artificial intelligence and massive analysis of integrated data oriented to the epidemiological control of the disease COVID-19.
Read more about this call or visit the website.
DEPARTMENT OF SCIENCE AND TECHNOLOGY NANO MISSION: Short-term Research Grant special call for Nano Coating COVID-19
Subsidy: max. Rs. 25-30 lakhs (including overhead)
Deadline: expired
Consortium: India: mostly research organizations that their findings can be transferred to the partnering Industry or a Start-up.
Scope:
- Antiviral Nano-coatings for materials to be used on appropriate material for producing anti-COVID-19 Triple Layer Medical masks and N-95 respirator or better masks in large quantities;
- All components of Personal Protective Equipment (PPE) for safeguarding the health of all health care workers against COVID-19 with industrial partners for scaling up production.
NIH: Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)
Subsidy: $500,000 Direct Costs (exclusive of third-party facilities and administration F&A costs)
Deadline: expired
Project duration: 5 years
Consortium: only the US entities are eligible
Scope: Subsidy is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH “to develop, validate, improve, and implement serological testing and associated technologies.” The purpose of this subsidy is to establish Serological Sciences Research Projects with the goals of:
- identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection;
- understanding the mechanisms driving the serological, humoral and cellular immune responses;
- determining host, genetic, and environmental modifiers of the immune response;
- and determining the serological correlates of disease pathogenesis and protection against future infection;
- defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. These U01 Research Projects will be part of a Serological Sciences Network (SeroNet). Institutes involved: National Cancer Institute (NIC), National Institute of Allergy and Infectious Diseases (NIAID)
Novo Nordisk Fonden- Support for projects seeking to mitigate the health consequences of the coronavirus (Covid-19) epidemic in Denmark
Subsidy: max. 5M DKK
Deadline: expired
Consortium: Applicant from public institutions/authorities or private not-for-profit organizations (e.g. NGOs) in Denmark participating in the fight against the coronavirus epidemic.
Scope: The aim is to mitigate the health consequences of the coronavirus epidemic in Denmark. Projects must be able to be initiated immediately but must be of such a nature that the knowledge gathered in the project is made available and can be utilized in similar situations in the future. Aid can be applied for in 3 areas:
- Scientific projects that test new treatments, techniques/technologies or preventative measures that can be used quickly to deal with the health system’s challenges in the current situation. Who can apply? Researchers in hospitals, professional colleges and universities.
- Informational measures that can improve communication with citizens and knowledge of the health management of the crisis. Who can apply? Authorities and partners.
- Social measures to meet the special health needs of vulnerable groups in connection with the crisis. Who can apply? Authorities, NGOs and other not-for-profit organizations.
Nordic Trial Alliance Invites Proposals for Nordic COVID-19 Activities
Subsidy: max. 500,000 NOK
Deadline: expired
Consortium: Participants of at least 3 different Nordic (Norway, Sweden, Finland, Denmark, Iceland) research performing organisations, public sector, patient organisations or other relevant organisations are eligible to apply. Companies are not eligible to receive funding but can take part on their own costs.
Scope: Due to the ongoing COVID-19 pandemic, there is a huge need for new knowledge related to the SARS-CoV-2 virus infection in order to develop vaccines and treatments.
A proposal could for example include (one or several) activities related to:
- Knowledge transfer
- Infrastructure establishment
- Nordic coordination of national initiatives incl. Trials
- Planning of joint Nordic initiatives
- Data sharing and interoperability
- Establishing networks
- Monitoring
- Preparedness for future pandemics
ACADEMY OF FINLAND: Call for applications: special funding for research on COVID-19 epidemic and the mitigation of its effects
Subsidy: up to €200,000 (per sub-application)
Deadline: expired
Consortium: Finnish research organisations (universities, higher education institution, research institutes and other research organisations) that have Academy-funded research relevant to the objectives of this call.
Scope: The objective of the Academy of Finland’s special funding for research on the COVID-19 epidemic is to support and accelerate research into the current coronavirus epidemic and the mitigation of its effects and to support the utilisation of the research in society. The aim is to quickly redirect research already underway to support the fight against the COVID-19 epidemic and reduce its consequences.
ZonMw/NWO funding for research to COVID-19 program will open soon!
Subsidy: available for this program is €27M. This new program will focus on different types of research (from fundamental research to action research). Both for short-term and long-term solutions. The program will focus on the following 3 research pillars:
- Predictive diagnostics and treatment
- Care and prevention, including transmission
- Social consequences of the corona crisis and measures against it.
Deadline: expired
Scope: ZonMw will make the subsidies available for each focus area in 3 ways:
- Fast track method: subsidies are available for problems and questions that needs to be solved quickly to combat this pandemic. Applications for this procedure will be submitted by invitation as soon as possible.
- Thematic bottom-up rounds for research proposals
- Policy and practical impulses aimed at small projects and studies. This is aimed at quickly and briefly addressing concrete policy questions and providing practical impulses.
More information about this call (in Dutch)
FNRS: SPECIAL CALL CORONAVIRUS (Crédits Urgents de Recherche)
Subsidy: varies per project (not specified); Teams that have already started research on the coronavirus or are about to do so can submit a claim (limited to €60,000) for costs incurred for the period 1 April – 31 August 2020.
Deadline: expired
Consortium: Belgium Wallonië: The Promoter must be: a Qualified Researcher, Senior Research Fellow or Research Director of the F.R.S.-FNRS or an academic or a scientist appointed on a permanent or probationary basis within one of the 6 FWB universities. The project may be carried out in collaboration or within a university hospital provided that the promoter meets the eligibility conditions.
Scope: A better understanding of the current Coronavirus epidemic requires urgent scientific research. As a reference agency for research funding, the FNRS has the responsibility to respond and release funds to organize calls to mobilize the FWB’s scientific communities and help them contribute to the growing international efforts. The following themes, included in the priorities set by the WHO, are eligible:
- Epidemiological and translational studies;
- Physiopathogenesis of the disease (virus-host interactions and immune response);
- Infection prevention and control measures in the health care setting (including the best ways to protect health workers) and in community settings;
- Projects aiming at the development of tests in clinical biology/screening are also eligible.
EIT Health- Headstart covid-19 solutions
Subsidy: €50,000
Deadline: expired
Consortium: open for European SMEs, spin-offs and start-ups.
Scope: the aim is to support healthcare start-ups with valuable solutions that can enable the community and health systems to fill in the gap until COVID-19 vaccines are ready. Product/projects must be at least at TRL8. Targeted topics/technologies (only digital solutions):
- AI driven mHealth
- Digital Health wearables, devices and sensors
- Diagnose
- Mental Health
- Epidemiology
- Solutions to support current crisis situations at hospitals (e.g. stock management, patients journey solutions).
The following will not be considered: new tests, drug development, new ventilators equipment.
EDCTP- Mobilisation of funding for COVID-19 research in sub-Saharan Africa –
Subsidy: max. €500,000 per project
Deadline: expired
Consortium: at least 3 independent legal entities, of which 2 in Participating States and 1 in a Sub-Saharan African country.
Scope: Support research activities in sub-Saharan Africa to manage and/or prevent the spread of the current COVID-19 outbreak. At least 1 of the following research gaps should eb addressed:
- Understanding of the natural history of infection to better define the period of infectiousness and transmissibility; improve surveillance capabilities.
- Promote the development, adaptation, evaluation, and implementation of point-of-care diagnostic tests.
- Support standardised, best evidence-based approaches for clinical management and better health outcomes for patients by contributing to the implementation of randomised, controlled trials for diagnostics and therapeutics as promising agents emerge, taking usability, including multi-centre/country trials and access in resource-constrained settings, into account.
- Validation and adaptation of existing serological tests, including those that have been developed by commercial entities, and establishment of biobanks and serum panels of well characterised COVID-19 sera to support such efforts.
PRACE support to mitigate impact of COVID-19 – Fast Track Call for Proposals pandemic
Subsidy: about 30 million to 50 million core hours (PRACE facilitates its computing resources (supercomputers)).
Deadline: expired
Consortium: Researchers from academia, from research institutes, and from commercial organisations (industry) based in Europe are eligible to apply.
Scope: PRACE is welcoming project proposals requesting computing resources to contribute to the mitigation of the impact of the COVID-19 pandemic. This applies, without being exhaustive, to the following topics:
- Biomolecular research to understand the mechanisms of the virus infection
- Bioinformatics research to understand mutations, evolution, etc.
- Bio-simulations to develop therapeutics and/or vaccines
- Epidemiologic analysis to understand and forecast the spread of the disease
- Other analyses to understand and mitigate the impact of the pandemic
Read more about this call or visit the PRACE website.
The Amazon Web Services Diagnostic Development Initiative (DDI)
Subsidy: $20,000,000 (total budget). Funding will be provided through a combination of AWS in-kind credits and technical support to assist research teams in harnessing the full potential of the cloud to tackle this challenge.
Deadline: expired
Consortium: Open to accredited research institutions, research consortia, and private entities that are AWS customers. Entities that are using AWS to support research-oriented workloads for the development of point-of-care diagnostic and other diagnostic techniques.Scope: Innovation in rapid and accurate patient testing for COVID-19, and other diagnostic solutions to mitigate future outbreaks. Accurate testing and diagnosis at point-of-care or regional locations for patients with COVID-19 is critical to early intervention and treatment. AWS is offering technical support and providing AWS promotional credits to support the use of AWS services to advance diagnostic research for selected institutions and companies.
Read more about this call or visit the website.
British Society for Antimicrobial Chemotherapy (BSAC)
Subsidy: £25,000
Deadline: expired
Consortium: Applications are open worldwide to all organizations
Scope: the aim is to support researchers in better understanding and addressing COVID-19 outbreak.
Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA) Request for Information (RFI) – CoV Pandemic Response
Subsidy: no limit (This request is Market Research to determine the capability of the industrial base to respond to the 2019-nCoV pandemic. At this time, funding has not been identified for any prototype projects under this request).
Deadline: expired
Consortium: Submission is open to all entities of the US Defense Industrial Base, not just MCDC members. Should a non-MCDC member be selected for award, that entity would be required to join the MCDC prior to award execution. Foreign firms with no US-based affiliate are also eligible.
Scope: The focus is on the following areas:
- Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, within 1-4 months
- Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening.
- Information systems and technology the US Government can use in a handheld Point-of-Care device to collect, screen, collate, report, and monitor disease infection and pandemic spread on a micro and macro level.
- Therapeutics: Drugs and/or drug/device combinations, or platforms currently under development demonstrating efficacy in post-exposure, pre- and post-symptomatic studies for any CoV strain, and capable of achieving EUA from the FDA within the next 3 months for this ongoing SARS-CoV-2 pandemic.
- Prophylactics: Drugs or vaccines currently under development demonstrating pre-exposure in vivo efficacy or in vitro activity against any or all strains of CoV. Antibody technology, accelerating the discovery, development, manufacturing and prediction of success for these technologies can be considered.
- Clinical Trials: Opportunities to expeditiously conduct clinical trials for any technology that will require evaluation for FDA approval, will be considered.
Read more about this call or visit the MCDC website.
The Lundbeck foundation- Coronavirus research
Subsidy: max. 5M DKK
Deadline: expired
Consortium: Applicants must be affiliated with Danish universities or hospitals and with local authorities, patient associations, think-tanks or similar organisations.
Scope: The foundation aims to provide funding for biomedical science research activities with the potential to mitigate the impact of the COVID-19 pandemic. The funding is available for research-based projects with a patient focus. Projects must have the potential for direct impact in this acute situation and therefore be able to be initiated without delay.
RVO- Stimulering E-Health Thuis (SET) Coronavirus
Subsidy: €50,000
Deadline: expired
Consortium: A care provider (formal or informal) to clients living at home or aimed at returning home. This includes, for example, health organizations, district nursing, GGZ providers and hospitals.
Scope: The care of vulnerable elderly people living at home or people with a chronic illness or disability is under pressure due to the COVID-19 and the measures to prevent the virus from spreading. Healthcare organizations therefore quickly need more technological options to provide remote care. The proposed activities contribute to the continuity of remote care for clients living at home during the corona crisis, or the activities are aimed at removing the obstacles resulting from this crisis.
Read more about this call or visit the RVO website.
ZonMw extra funding for creative solutions COVID-19
Subsidy: Start impulse max. €7,5000 and Project impulse: €7,500-15,000
Deadline: expired
Consortium: all Dutch innovators can apply
Scope: The aim is to fund creative solutions to the challenges regarding COVID-19. On the one hand, this concerns practical technological solutions in (hospital) care, such as medical devices. On the other hand, it is about innovative ideas to help vulnerable groups and their care and care providers in providing the right care and support. This concerns solutions that fall outside regular care and welfare activities. There are two financial impulses:
- Start Impulse: intended for developing and potential piloting of your project
- Project Impulse: important condition for this is that the creative solution meets the needs of the target group.
Looking for funding?
How can we help you on your innovation journey?
Neeltje Ramnath-Willems
+31 (0)6 53 82 46 94
